Myo-inositol exerts behavioral effects in animal models of psychiatric disorders and is effective in clinical trials in psychiatric patients. Interestingly, epi-inositol exerts behavioral effects similar to myo-inositol, even though epi-inositol is not a substrate for synthesis of phosphatidylinositol. We postulated that the behavioral effects of epi-inositol may be due to its effects on gene expression. Yeast INO1 expression was measured in northern blots. INM1 was determined by ␤-galactosidase activity in a strain containing the fusion gene INM1-lacZ integrated into the genome. Epi-inositol affects regulation of expression of the INO1 gene (encoding inositol-1-P synthase), even though it cannot support growth of an inositol auxotroph (suggesting that, as in mammalian cells, it is not incorporated into phosphatidylinositol). Like myo-inositol, although to a lesser extent, epi-inositol causes a significant reduction in INO1 expression, and reverses the lithium-or valproate-induced increase in INO1 expression. However, it does not affect regulation of INM1 (encoding inositol monophosphatase), the expression of which is up-regulated by myo-inositol. The observed regulatory effects of epi-inositol on expression of the most highly regulated gene in the inositol biosynthetic pathway may help to explain how this inositol isomer can exert behavioral effects without being incorporated into phosphatidylinositol.
Introduction
The six-carbon polyol inositol is a uniquely versatile biological compound. 1 Myo-inositol is the major naturally occurring isomer of nine possible inositol isomers. 2 Myo-inositol is critical for the phosphatidylinositol (PI) cycle as a substrate for PI synthesis. 3 Inositol phospholipids and inositol phosphates are also key cell membrane structural elements and signal transduction messengers. 3, 4 Myo-inositol may play an important role in bipolar disorder (manic depressive illness), a devastating condition characterized by recurring bouts of mania and depression. For decades, lithium has been the most effective treatment for bipolar disorder. 5 Because lithium uncompetitively inhibits inositol monophosphatase, the inositol depletion hypothesis was proposed as a possible explanation for the therapeutic mechanism of lithium. 3, 6 According to this hypothesis, inhibition of the monophosphatase leads to depletion of inositol from the brain, resulting in down regulation of the PI cycle. While many studies point to inositol depletion as a possible therapeutic mechanism of action of lithium, 7, 8 the results of several experiments have been used to argue against this hypothesis. One argument is that epi-inositol exerts behavioral effects similar to myo-inositol in animal models of psychiatric disorders, even though epi-inositol is not a substrate for synthesis of PI. 9 However, this argument does not take into account the potential role of inositol in the regulation of gene expression.
The relative efficacy of epi-inositol compared to myo-inositol varies in different experimental paradigms (summarized in Table 1 ). It was reported that epi-inositol, like myo-inositol, reversed lithium-pilocarpine seizures. 14, 16 Epi-inositol was approximately 50% as effective as myo-inositol in reversing lithiumpilocarpine seizures. 16 This finding suggests that epiinositol could enter the PI cycle. Accumulation of cytidine-monophosphate-phosphatidate (CMP-PA) in CHO cells or rat cerebral cortex during lithium treatment is reversible with myo-inositol. 17 Epi-inositol was about 30-40% as active as myo-inositol in reversing the accumulation. 13 Myo-inositol has been found to have antidepressant and anti-anxiety effects in controlled studies in patients. 18, 19 In animal models, myo-inositol has been reported to be active in the elevated plusmaze model of anxiety 20 and in the Porsolt swim test 21 Recently, epi-inositol was studied in the elevated plus maze model of anxiety and, surprisingly, was found to be more active than myoinositol. 15, 22 However, more recent experiments in the Porsolt swim test model of depression found comparative results for epi-inositol and myo-inositol similar to that found by Patishi et al 16 for reversal of Li-pilocarpine seizures (Shaldubina et al, unpublished data). In summary, epi-inositol has been shown to affect behavior in several paradigms, although the efficacy of epi-inositol vs myo-inositol varies greatly. If epi-inositol is not incorporated into PI, the behavioral effects of this isomer may be related to a regulatory effect of epiinositol on gene expression.
The eukaryote in which regulation of inositol biosynthesis has been characterized in the greatest detail is the yeast Saccharomyces cerevisiae. Because of the striking degree of conservation of function between yeast and higher eukaryotes, the yeast system has long been exploited to understand complex eukaryotic cellular processes. In yeast, myo-inositol exerts a profound effect on the regulation of gene expression. 23 Many of the genes that encode components of the PI pathway have been cloned in yeast, and regulation of inositol metabolism in yeast is understood at a molecular level. 24 The genes for inositol biosynthesis in yeast are depicted in Figure 1 .
Expression of the structural gene INO1, coding for inositol 1-P synthase, is dramatically repressed in the presence of inositol. The products of the positive transcriptional regulators INO2 and INO4 form a heterodimer that leads to derepressed expression of INO1 in the absence of inositol. The negative regulator Opi1p is required for repression of INO1 in the presence of inositol, and defects in this gene result in constitutive expression of INO1 and an inositol excretion phenotype. The regulatory gene INO2 is controlled in a similar manner, ie, its expression is increased about twofold in the absence, and repressed in the presence of inositol. INM1, one of at least two yeast genes that code for inositol monophosphatase, is also regulated by inositol. 25 However, in contrast to INO1 and INO2, INM1 expression is slightly increased in the presence Molecular Psychiatry Figure 1 The genes for inositol biosynthesis in Saccharomyces cerevisiae. Glucose-6-P(Glc-6-P) is converted to inositol-1-P (I-1-P) by the INO1 gene product inositol-1-P synthase. I-1-P is dephosphorylated to inositol by inositol monophosphatase, encoded by at least two genes, INM1 and INM2. The products of positive regulatory genes INO2 and INO4 form a heterodimer that derepresses transcription of INO1 in the absence of inositol. In the presence of inositol, the negative regulator encoded by the OPI1 gene causes reduced transcription of INO1 by an unknown mechanism. of inositol. Inositol is a key metabolic sensor, and inositol levels play a major role not only in regulating inositol biosynthesis, but also in regulation of phospholipid biosynthesis and in the glucose and unfolded protein response pathways. 23 Depletion of intracellular inositol leads to the derepression of many genes that are required for inositol and phospholipid biosynthesis. 24 Conservation of function has been demonstrated from yeast to humans, and homologs of the yeast genes INO1 and INM1 are present in the human genome. An NCBI Gene Bank 26 sequence of human IMPA1 was compared with yeast INM1. Sequence of human MIP synthase was compared to yeast INO1. Human IMPA1 and yeast INM1 shared 43% similarity in amino acid sequence. Human myo-inositol phosphate synthase and yeast INO1 exhibited 56% amino acid similarity. The high degree of amino acid sequence similarities were apparent despite little homology at the DNA sequence level. In addition to the genes for inositol biosynthesis, particularly relevant to neurobiological studies is the functional homology between yeast secretory genes and mammalian genes involved in neurotransmitter release. 27 An understanding of how regulation of inositol biosynthesis is perturbed by antibipolar treatments may thus have far-reaching implications for understanding their therapeutic mechanisms.
We have recently shown that both lithium and valproate cause a decrease in inositol biosynthesis in yeast via different mechanisms. 28 Lithium inhibits inositol monophosphatase in yeast, as it does in cells of higher eukaryotes. In contrast, valproate causes a decrease in inositol monophosphate synthesis, most likely by inhibiting the inositol-1-P synthase reaction (that converts glucose-6-P to inositol-1-P). Growth in the presence of either drug leads to an increase in expression of INO1 and INO2, and a decrease in expression of INM1. We postulated that effects on gene expression could underlie the psychoactive mechanisms of these drugs in mammals, and might explain the observed effects of epi-inositol on behavior. In this study, we demonstrate that epi-inositol, like myo-inositol, affects expression of INO1.
Methods

Materials
Yeast extract, peptone and ammonium sulfate were from Fisher Scientific. Myo-and scyllo-inositol, mannitol, valproic acid, lithium chloride, amino acids, glucose, and TRIS were from Sigma. Epi-inositol was supplied by Dr Atsushi Takahashi, Hokko Chemical Industry Co, Kanagawa, Japan. L-chiro-inositol was a gift from William R Sherman, Washington University. Phenol was obtained from Gibco BRL. Chloroform was from Fisher. Hybridization buffer was from Clontech. MOPS was obtained from Amresco. Radiolabled UTP (␣-P 32 UTP) was from Dupont, NEN Research Products and American Radiochemical.
Yeast strains
The wild-type yeast strain was SH302 (derivative of PMY168, genotype trp1-⌬63 his3-⌬200 ura3-52 leu2-⌬1). The inositol auxotroph strain was SH306, which is isogenic with SH302 except that it has the null ino1 allele ino1::HIS3). The strain containing the INM1-lacZ fusion was MMY3(SJ), genotype met6 ura3::YIp357R-INM1-lacZ URA3, which is essentially identical to MMY3. 25 
Effect of inositol isomers on growth of inositol auxotroph
To prepare overnight cultures, yeast cells were inoculated from colonies on YPD plates (yeast extract (1% w/v), bacto-peptone (2% w/v), glucose (2% w/v), agar (2% w/v)) into minimal synthetic medium (glucose (2% w/v), the essential amino acids and nucleotides (histidine (10 mg l ) and uracil (10 mg l −1 )), vitamin free yeast base (0.069% w/v), ammonium sulfate (0.201%), vitamins 29 and myo-inositol (75 M)) and grown overnight at 30°C with aeration. Cells were harvested by centrifugation (10°C, 5000 rpm, 5 min), washed twice with 50 ml inositol-free minimal medium, and resuspended in 25 ml of this medium. Two-milliliter experimental cultures were inoculated to an A 550 of 0.07 (ෂ10 6 cells ml
) in minimal medium containing the indicated supplement (epi-, L-chiro-, scyllo-or myo-inositol). Controls contained mannitol (osmotic control) or no supplement. Cultures were incubated for 24 h at 30°C with aeration. Aliquots were taken at the indicated times, and viable cells were determined by serial dilution and plating on YPD plates. Cell survival in the indicated medium is depicted relative to the number of viable cells in medium containing 40 M myo-inositol.
Measurement of INO1 expression
Cells were grown in minimal synthetic medium in the presence of the indicated concentration of lithium, valproate, or inositol, and harvested in the late logarithmic phase of growth. Cells were disrupted with glass beads. RNA was isolated by hot phenol extraction, fractionated on an agarose gel, and transferred to nylon. The blots were hybridized with a 32 P-labelled INO1 riboprobe, followed by a riboprobe for the constitutively expressed ribosomal protein gene TCM1 to normalize for total RNA. RNA probes for northern analysis were synthesized using the Gemini II core system from plasmids linearized with a restriction enzyme as follows (plasmid, restriction enzyme, RNA polymerase): pJH310, HindIII, T7 (INO1); pAB309, EcoRI, SP6 (TCM1). 30 Hybridization with the pJH310-derived probe 31 detects a single 1.8-kb INO1 transcript, which is not detected in RNA from strains containing a deletion of the INO1 gene. The results of northern blot hybridization were visualized by autoradiography, and relative levels of INO1 and TCM1 were quantitated by phosphorimaging.
Measurement of INM1 expression
MMY 3(SJ) cells (25-ml cultures) were grown in the presence or absence of inositol for several generations. Cells were harvested by centrifugation at the indicated times, and resuspended in 1 ml breaking buffer (100 mM Tris-HCl (pH 8), 1 mM DTT and 20% glycerol). The suspensions were vortexed with glass beads 10 times for 30-s intervals, cooling the cells on ice between intervals. Extracts were clarified by centrifugation at 14 000 g for 15 min, and supernatants were stored at −80°C. Protein concentration was determined by the method of Bradford, 32 using BSA as the standard. ␤-galactosidase activity was assayed by measuring the conversion of o-nitrophenyl-␤-d-galactopyranoside (ONPG) to o-nitrophenol. The reaction mixture for each assay contained 1.32 ml buffer (breaking buffer described above, with 1 mM DTT and PMSF added fresh) and 330 l cell extract. The reaction mixtures were incubated at 30°C for 5 min, and the reaction initiated by addition of 660 l of 4 mg ml −1 ONPG (freshly prepared), noting the time of addition. At 5, 10, and 15-min intervals, 700 l of reaction mix was added to a microfuge tube containing 500 l 1 M Na 2 CO 3 and vortexed vigorously to terminate the reaction. A 420 was determined, and units of ␤-galactosidase activity were defined as A 420 min −1 mg −1 of total protein × 1000.
Results
Effect of inositol isomers on growth of inositol auxotroph ino1
The yeast INO1 gene, which codes for inositol-1-P synthase, is essential for the biosynthesis of myo-inositol. 23 Ino1 mutant cells cannot grow in synthetic medium lacking inositol, but grow well if media are supplemented with 10 M myo-inositol. 33 To determine whether other inositol isomers could support growth of the ino1 mutant, cells were grown in medium supplemented with myo-, epi-, chiro-or scyllo-inositol, or with mannitol (osmotic control). Survival of cells grown in myo-inositol supplemented medium was defined as 100%. As shown in Figure 2 , as little as 5 M myo-inositol supported growth of the mutant. In contrast, the mutant was unable to grow in the presence of 40 M epi-, chiro-or scyllo-inositol.
Regulation of INO1 expression by inositol isomers
Inositol is a key regulator of its own synthesis and of phospholipid biosynthetic pathways as well as several signal transduction pathways in yeast. 23 To determine if epi-inositol, like myo-inositol, regulates gene expression in yeast, we compared the effects of these isomers on expression of INO1, which is dramatically repressed during growth in the presence of myo-inositol. Previous studies have shown that INO1 expression is fully repressed in the presence of 40 M myo-inositol (summarized in Carman and Henry 23 ). As shown in Figure 2 Epi-inositol does not support growth of the inositol auxotroph ino1. Ino1 mutant cells were grown for 24 h in synthetic medium containing the indicated supplement. Cell viability was determined by serial dilution and plating on YPD plates. ANOVA F (10) = 37.8, P Ͻ 0.001. Post hoc Scheffe test analysis of specific effects showed significant differences between controls vs myo-inositol 5, 10 and 40 M: P = 0.007, P = 0.0005 and P = 0.0001, respectively. Each bar represents the mean of two repeated experiments with four replicate aliquots in each experiment. Each experiment was done from a fresh culture. 
Epi-inositol, like myo-inositol, reduces the lithiumand valproate-induced increase in INO1 expression
We have shown previously that both lithium and valproate cause a decrease in intracellular inositol, and an increase in INO1 expression. 28 The drug-induced increase in INO1 does not occur if cells are grown in the presence of exogenous myo-inositol. These findings were observed during growth in therapeutically relevant concentrations of the drugs. To achieve intracellular concentrations of lithium in the therapeutic range (0.6-1.2 mM), it was necessary to add extracellular lithium to 7.5-15 mM, because yeast cells have several powerful mechanisms to exclude deleterious cations. 28 Since there is no evidence to suggest that valproate uptake is different in yeast and mammalian cells, valproate was added at 0.1-0.6 mM, the therapeutic range. Viability of the wild-type strain used in this study was not affected at these concentrations of lithium or valproate.
To determine if epi-inositol also prevents the druginduced increase in INO1, wild-type cells were grown in the presence of epi-inositol and lithium or valproate, and INO1 expression was examined in northern blots. Growth in the presence of 7.5 and 15 mM lithium led to 4.4-and 5.6-fold increases in INO1 expression, respectively (Figure 4) . Addition to the growth medium of either myo-or epi-inositol led to a significant reduction in the lithium-induced increase in INO1 expression, at both lithium concentrations. Forty M myo-inositol reduced the lithium-induced increase in INO1 expression by almost 100%. Epi-inositol reduced INO1 expression in 7.5 and 15 mM lithium by 77% and 65%, respectively. Scyllo-inositol and mannitol had no effect.
Growth of cells on media containing 0.3 or 0.6 mM valproate increased INO1 expression by 10 and 16-fold, respectively ( Figure 5 ). Addition of 40 M myo-inositol completely reversed this effect, even at a higher concentration of valproate. Epi-inositol reversed the valproate-induced increase in INO1 expression by 60% in 0.3 mM valproate and 40% in 0.6 mM valproate. Thus, epi-inositol was effective, although less than myo-inositol, in reversing the valproate-induced increase in INO1 expression.
Figure 5
Epi-inositol reverses the valproate-induced increase in INO1 expression. Wild-type cells were grown in synthetic medium with the indicated supplements. INO1 expression relative to TCM1 was determined by northern blot analysis. ANOVA F (6) = 18.3, P = 0.001; Post hoc Scheffe test indicated a significant difference when myo-and epi-inositol were compared to the control in the presence of 0.3 mM valproate: P = 0.007 for myo-inositol and P = 0.04 for epi-inositol, and a significant difference when myo-inositol was compared to control in presence of 0.6 mM valproate P Ͻ 0.001. Each bar represents the mean of three experiments. Each experiment was done from a fresh culture.
Epi-inositol, unlike myo-inositol, does not cause an increase in INM1 expression
INM1 is one of at least two nearly identical yeast genes encoding inositol monophosphatase. 25, 34 In attempts to detect INM1 mRNA by northern analysis, an additional band, probably corresponding to INM2, was always detected with the INM1 probe. Because INM1 and INM2 differ in their 5′ regulatory sequences, it was possible to measure INM1 expression using an INM1-specific reporter construct. To make this construct, a 461-bp sequence containing the INM1 promoter region and 9 bp of coding sequence was cloned into the vector Yip357R, in frame with the lacZ gene, and integrated into the genome of a wild-type strain. 25 In the strain (MMY3) containing the INM1-lacZ fusion, INM1 expression, as measured by the ␤-galactosidase reporter, is increased in the presence of myoinositol. This was especially interesting because the gene for inositol-1-P synthase, INO1, is repressed by myo-inositol. To determine if epi-inositol, like myoinositol, affects INM1 expression, wild-type cells containing the INM1-lacZ fusion gene were grown in the presence or absence of 75 M myo-or epi-inositol. Aliquots were removed at the indicated times, and ␤-galactosidase was assayed. As indicated in Figure 6 , ␤-galactosidase activity was increased during growth in the presence of myo-inositol, while epi-inositol had no effect. These results indicate that myo-, but not epiinositol, increases INM1 expression.
Discussion
Because epi-inositol exerts some effects on rat behavior, but is not apparently incorporated into PI, we have examined possible mechanisms for this activity using a yeast model. In yeast, epi-inositol cannot support the growth of an inositol auxotroph ( Figure 2) . One possible reason is that the yeast PI synthase may not recognize epi-inositol, in which case it is not incorporated into PI. This would be in agreement with the findings that the mammalian PI synthase does not recognize epi-inositol. 9 Alternatively, epi-inositol may be incorporated into yeast PI, but the epi-lipid may not be able to carry out required functions as does the myo-lipid. Inositol also has an important regulatory function, independent of its role as a component of PI.
In the presence of myo-inositol, the genes in many phospholipid and phospholipid precursor pathways are repressed. 24 The most dramatic repression is seen in the response of INO1, which is repressed at least 30-fold in the presence of myo-inositol. We wished to determine if epi-inositol exerts a similar effect on gene expression. This work shows that epi-inositol does lead to reduced INO1 expression when added to inositol-free medium, although to a lesser extent than does myo-inositol (Figure 3) . Furthermore, like myo-inositol but to a lesser degree, it reverses the increase in INO1 expression caused by lithium and valproate (Figures 4  and 5) . Therefore, epi-inositol is biologically active in its ability to affect regulation of the inositol biosynthetic pathway.
It is intriguing that the regulatory effects of epi-inositol are similar to those of myo-inositol with respect to INO1 regulation (Figures 3-5 ), but different with respect to INM1 regulation ( Figure 6 ). This most likely reflects the different mechanisms whereby these two genes are regulated. INO1 expression is derepressed when inositol is limiting. Derepression is mediated by Ino2p and Ino4p heterodimers which bind to the UAS INO and activate transcription. In contrast, while INM1 has a UAS INO , expression of this gene is increased in the presence of myo-inositol. It is not currently known whether INO2, INO4, or OPI1 control expression of INM1. Thus, the mechanisms whereby inositol regulates the two genes are different. The current report suggests that epi-inositol can affect regulation of INO1 but not INM1. Therefore, it can be a useful tool with which to understand how INM1 expression is regulated.
These findings have further implications for understanding the molecular mechanisms underlying the regulation of inositol biosynthesis. According to the hypothesis of Patton-Vogt, 35 an increase in phosphatidic acid (PA) is the likely 'signal' for derepression of INO1. Thus, during inositol starvation, PA accumulates because CMP-PA is not converted into PI. PA levels are sensed by a presently unknown mechanism, which effects an increase in expression of INO1 when PA levels increase. Viewed in light of this hypothesis, the observed repressed levels of INO1 might suggest that PA does not accumulate in the presence of epiinositol, possibly indicating that the isomer is incorporated into a (non-functional) PI.
